Admissions:
Sterling Digital (AQSE:ASIC), the Company set up to initiate Bitcoin mining operations at low-cost stranded gas sites in the US, announced the Admission of its entire issued share capital to trading on the Access Segment of the Aquis Stock Exchange Growth Market. The placing raised £4m at 5p giving a market capitalisation on Admission of approximately £7.5m.
Delta Gold Technologies (AQSE:DGQ), the technology Company focused on developing IP in the quantum computing sector, announced its first day of dealings on the Aquis Stock Exchange Growth Market. The Company raised £2.5m at 10p giving a market capitalisation of approximately £5.9m.
Delistings:
Pmgr Securities (PMGZ.L) left the Main Market
What’s baking in the oven?
Potential** Initial Public Offerings:***
27th November: Power Probe, the producer of automotive electrical diagnostic tools for professional service technicians, announced its intention to IPO onto AIM. The suite of electrical diagnostic tools and accessories offered by the Group are compatible with all major vehicle engine types and manufacturers and can be used in all types of commercial and passenger road vehicles, including light and heavy goods vehicles and motorcycles. The Directors believe the Group is well positioned to benefit from a number of positive, long-term tailwinds in this market, including the non-cyclical growth of the global Car Parc, the increasing average age of vehicles, and increasing vehicle complexity. The Company's main country of operation is the United States. Offer details TBC and timing expected mid December 2025.
25th November: Connecting Excellence Group, the international executive recruitment group with a Bitcoin treasury strategy, announced its intention to IPO onto the Aquis Stock Exchange Growth.
Admission is expected to occur on or around the 9 December under the TIDM 'XCE'. As part of its Admission to Aquis, the Company intends to raise a minimum of £1.5m by way of a placing and subscription of New Ordinary Shares at 2.1 pence per share, to support XCE's Bitcoin treasury strategy and future growth. The Company’s flagship subsidiary, Spencer Riley Limited, was founded in 2014 and is headquartered in Leeds, UK. It is an international executive search firm delivering £1.52m in revenue and £659,000 in gross profit in the last financial year. Since 2021, it has realised a compound annual revenue growth rate of 37%.
Market Movers
18 November: Roquefort Therapeutics (ROQ.L) proposes to change its name to Coiled Therapeutics plc. The Company will cancel the listing of its ordinary shares on the Equity Shares (Transition) category of the Official List and trading on the Main Market for listed securities of the London Stock Exchange, and make application for its ordinary share capital to be admitted to trading on the AIM market and carry out an equity placing by the issue of new ordinary shares to raise a minimum of £10.5m conditional on Admission.
19 November: All Things Considered Group (AQSE: ATC); The independent music Company which delivers representation, services and creative commercial solutions announced a conditional equity fundraising of £8.6m and subsequent move to AIM. Admission to AIM is expected to occur on or around 17 December. Net proceeds of the Fundraising will provide additional working capital and a strengthened balance sheet to continue ATC's growth strategy.
Banquet Buffet****
Alien Metals Limited 0.12p £11.82m (UFO.L)
The minerals exploration and development Company announced that its wholly owned subsidiary, Alien Metals Australia Pty Ltd (AMA) has entered into a conditional sale agreement with GreenTech Metals Limited (ASX: GRE) in respect of a 70% interest in the Munni Munni Project and surrounding tenements totalling 180km sq located in the West Pilbara. AMA will retain a 30% interest in the Project and will enter into a joint venture agreement with GreenTech upon completion of the Sale Agreement.
As a condition to completion of the Transaction, GreenTech is to complete a minimum capital raising of A$3m via a share placement.
CleanTech Lithium 5.25p £11.47m (CTL.)
The exploration and development Company advancing sustainable lithium projects in Chile notes a legal claim has been made by the vendors of 23 mining concessions at Laguna Verde acquired by its wholly owned subsidiary, CleanTech Laguna Verde SpA (CLV), pursuant to a sale and purchase agreement (SPA) announced on 22 April 2024. On 24 November 2025, the directors became aware that a legal action has been brought against CLV in Chile with the purpose of seeking payment of the second instalment under the SPA. The payment was initially delayed (as announced 22 October 2024), but the ongoing delay in making that payment has given rise to the claim. The directors are satisfied that non-payment of the second instalment has no bearing on its application for the special lithium operating contract (CEOL) for Laguna Verde, which is to be applied for through a different CleanTech subsidiary when the process recommences.
ECO Animal Health Group 98.00p £63.69m (EAH.L)
The animal health Company announced its unaudited interim results for the six months ended 30 September 2025. As a result of increased volume plus price improvements and lower cost of sales, revenue and adjusted EBITDA are ahead of the Board's previously announced guidance set out in the 25 September 2025 AGM Trading Update. Group Revenue increased 19% to £39.4m (H1 2024: £33.2m) and Gross margins increased to 49.6% (H1 2024: 40.3%), driven by improved pricing and lower input costs. Cash balances increased to £18.6m (30 September 2024: £18.3m).
Hardide 7.25p £5.22m (HDD.L)
The provider of advanced surface coating technology announced that it has received orders from a major new North American customer in the energy sector with an aggregate value of £1.75m.
Discussions are continuing with this customer to plan for ongoing demand later in 2026, and the potential for higher demand in 2027 and thereafter. These orders are expected to benefit Group revenues in the first half of Hardide's current financial year ending 30 September 2026 (FY26) and are greater in value than initially forecast. The Board accordingly now anticipates revenue and financial performance for FY26 to be materially higher than its previous expectations.
IXICO 11.00p £10.19m (IXI.L)
The neuroscience imaging and biomarker analytics Company today announced that it has appointed two leading global experts in the field of Alzheimer's Disease (AD) and cerebrovascular disease as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory board with immediate effect. The announcement is being made as part of IXICO's participation in the18th CTAD conference (Clinical Trials on Alzheimer's Disease) which starts today. CTAD is an annual cornerstone event in AD clinical research, where IXICO will be presenting research on its capabilities for the accurate assessment of positron emission tomography (PET) imaging in clinical trials.
Northamber 29.50p £7.73m (NAR.L)
The distributor of AV and UC&C solutions announced that it has acquired Nuvias UC's UK Hardware Business, NUC Distribution (NUC) pursuant to a share purchase agreement following a hive down from Nuvias UC of the NUC Business. NUC is one of the leading providers of specialist Unified Communications (UC) equipment in the UK. The total consideration for the Acquisition is up to £7.1m in cash. Based on unaudited management accounts, for the 12 months to 30 October 2025, the NUC Business had revenues of £28.8m, Gross Profit of £3.2m and net assets were £5.0m as at 29 November 2025.
The Board believes the Acquisition will strengthen Northamber's position as one of the UK's most complete collaboration & AV technology distributors.
SpaceandPeople 229.00p £4.19m (SAL.L)
The brand experience, retail and promotional specialist announced a new three-year exclusive agreement with LNER, covering promotional events across its entire network of stations. This marks the beginning of a new partnership with LNER and significantly expands SpaceandPeople's presence in UK railway stations, adding high-footfall locations such as Newcastle, York and Doncaster stations to its portfolio. The Company anticipate strong demand from brand advertisers and retailers seeking activation opportunities across the network.
Solid State 147.5p £81.0m (SOLI.L)
The value-added component supplier and design-in manufacturer of computing, power, and communications products reports Interims to September 2025. There is a 38.6% increase in revenue to £85.7m with operating margins improving to 5.3% from 3% leading to a 216.6% increase in PBT to £3.8m. The H1 performance is benefitting from the delivery of a major communications order which more than offset ongoing softness within the industrial sector. Cash generation is a focus and remains strong and although net debt has increased to £7.1m to cover the large communications order, the dividend is being increased 10.8% to 0.92p. The order intake was slower in H1, although it has recovered strongly at the beginning of H2 and the Directors remain confident in meeting consensus market expectations. The Board is being strengthened by the appointment of a Non-Executive Deputy Chairman who has 35 years of experience in the defence, aerospace, and security sectors.
Time To ACT 9.00p £1.33m (AQSE:TTA)
The engineering-led group focused on technology for the energy transition supply chain announced that a core patent application within its GreenSpur activity has been approved for grant by the European Patent Office. The patent covers GreenSpur's proprietary flat strip coil architecture which enables the use of precision-formed conductive aluminium strip instead of traditional copper windings. The GreenSpur approach overcomes the inherently lower conductivity of aluminium compared to copper.
Wynnstay Group 328.0p £74.70m (WYN.L)
The agricultural supplies Group today issued its trading update for the year ended 31 October. The Board expects underlying trading results for the year to be modestly ahead of current market expectations with adjusted profit before tax of approximately £9.0m. The Group end the year with net cash (pre IFRS 16 leases) of £26.4m (2024: £32.8m). Early trading in the new financial year is in line with the Board's expectations. Audited results for the year ended 31 October 2025 will be released on Monday, 9 February 2026.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
